Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV Vaccine in Allogeneic Stem Cell and Lung Transplant Recipients
NCT06593210Phase 3Active, not recruiting
- Sponsor
- University Health Network
- Start
- Oct 2024
- Primary completion
- Mar 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of GSK3003899A in respiratory syncytial virus infection (RSV), sponsored by University Health Network. Primary endpoint: Humoral immunogenicity at 4 weeks. Started Oct 2024; status: active, not recruiting.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06593210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06593210.